MarketPeel
Insider Trading Intelligence
BH

Brendan Hannah

QNCX
CHIEF BUSINESS OFFICER · QUINCE THERAPEUTICS, INC. · CIK 0001929422
FILING MIX · LIFETIME80%/20%
BUYS
16
SELLS
4
TOTAL VALUE
$217.6K
COMPANIES
1
ACTIVE SINCE
Feb 2023
HOLDINGS NOW
365,000
AVG SELL PX
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Brendan Hannah, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+100.00%+6.80%-0.19%+6.99%+5.40%
14d7+100.00%+10.08%-1.61%+11.69%+11.10%
30d7+100.00%+25.51%+1.27%+24.24%+22.39%
60d7+85.71%+23.06%+3.43%+19.63%+23.16%
90d7+85.71%+152.72%+4.41%+148.31%+170.95%
180d7+100.00%+108.47%+9.89%+98.58%+110.54%
1y7+85.71%+2126.72%+15.22%+2111.50%+2401.19%
2y7(6 pending)+100.00%+1268.85%+44.22%+1224.64%+1224.64%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
QNCX · 365,000 shares · as of Jan 23, 2026
0150,000300,000450,000600,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 16 buys / 4 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
QNCX
QUINCE THERAPEUTICS, INC.
SALEGRANT
Stock grant
365,000365,000Jan 23, 2026Jan 23, 2026View →
QNCX
QUINCE THERAPEUTICS, INC.
SALE
CBO, COO & CCO
25,280199,720Dec 5, 2025Dec 6, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
SALE
CBO, COO & CCO
2,27145,168Dec 5, 2025Dec 6, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CBO, COO & CCO
25,280$0.94$23.8K361,827Dec 5, 2025Dec 6, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CBO, COO & CCO
2,271$0.55$1.2K336,547Dec 5, 2025Dec 6, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,736$1.20$45.3K334,276Jun 18, 2025Jun 20, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,736$0.13$4.7K37,736Jun 18, 2025Jun 20, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
450,000450,000Jan 28, 2025Feb 11, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
23,565$0.63$14.8K296,540Aug 21, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
2,280$0.61$1.4K267,975Aug 21, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
5,000$0.62$3.1K272,975Aug 21, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
2,500$0.61$1.5K262,271Aug 20, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
3,424$0.60$2.1K265,695Aug 20, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
2,155$0.58$1.2K259,771Aug 19, 2024Aug 21, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
SALE
CHIEF BUSINESS OFFICER AND COO
56,06147,439Jun 4, 2024Jun 5, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
CHIEF BUSINESS OFFICER AND COO
56,061$0.55$30.8K257,616Jun 4, 2024Jun 5, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
600,000600,000Feb 1, 2024Feb 1, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Oct 24, 2023Oct 25, 2023View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
71,762$1.22$87.5K201,555Aug 8, 2023Aug 9, 2023View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
225,000225,000Feb 1, 2023Feb 2, 2023View →
Other insiders · QNCX
Loading peer insiders…
About this filer
CIK 0001929422
ROLE
Chief Business Officer
PRIMARY
QNCX
COMPANIES
1
ACTIVE SINCE
Feb 2023
MARKETPEEL · /INSIDER/0001929422DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback